Scholarlink

Background and purpose <p>Cancer-related fatigue (CRF) is one of the most prevalent and debilitating long-term symptoms among cancer survivors, particularly those with gastrointestinal malignancies. Previous studies on Panax ginseng supplementation have shown inconsistent findings, and evidence in gastrointestinal (GI) cancer survivors remains limited. This study evaluated the efficacy and safety of standardized Panax ginseng extract in reducing CRF.</p> Material and methods <p>In this randomized, double-blind, placebo-controlled trial, 65 survivors (≥ 4&#xa0;months post-treatment) with moderate-to-severe CRF (Brief Fatigue Inventory [BFI] score &gt; 4) were allocated to receive either Panax ginseng extract (250&#xa0;mg/day) or placebo for four weeks. Fatigue severity (BFI total score) was assessed at baseline and post-intervention. Data analysis was performed with SPSS 27 software, where statistical significance was considered at <i>p</i> &lt; 0.05.Data were analyzed using ANCOVA, controlling for baseline scores. Effect size (Cohen’s d) and 95% confidence intervals (CI) were calculated.</p> Results <p>At baseline, mean fatigue scores were similar between groups (Intervention: 5.36 ± 1.18; Placebo: 5.35 ± 1.23). After four weeks, the intervention group demonstrated significant reductions in fatigue (3.99 ± 0.86 vs. 5.37 ± 1.27, <i>p</i> &lt; 0.001), with an adjusted mean difference of − 1.38 (95% CI: − 1.90, − 0.86; Cohen’s d =  − 1.26). Significant improvements were also observed in general activity, walking ability, mood, and enjoyment of life in the intervention group. No treatment-related adverse events were reported.</p> Conclusion <p>Short-term Panax ginseng supplementation significantly reduced fatigue and improved multiple dimensions of daily functioning in GI cancer survivors, with excellent tolerability. These findings support Panax ginseng as a potential adjunctive intervention for CRF management within supportive care. Larger multicenter studies with extended follow-up are warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The effect of ginseng extract on fatigue in cancer survivors: a randomized double-blind clinical trial

  • 期刊论文

  • 发表日期：

    2026年3月16日

查看全文
  • Azad Rahmani,
  • Zohreh Sanaat,
  • Hosein Nazemiyeh H,
  • Afzal Shamsi,
  • Musab Ghaderi

摘要

Background and purpose

Cancer-related fatigue (CRF) is one of the most prevalent and debilitating long-term symptoms among cancer survivors, particularly those with gastrointestinal malignancies. Previous studies on Panax ginseng supplementation have shown inconsistent findings, and evidence in gastrointestinal (GI) cancer survivors remains limited. This study evaluated the efficacy and safety of standardized Panax ginseng extract in reducing CRF.

Material and methods

In this randomized, double-blind, placebo-controlled trial, 65 survivors (≥ 4 months post-treatment) with moderate-to-severe CRF (Brief Fatigue Inventory [BFI] score > 4) were allocated to receive either Panax ginseng extract (250 mg/day) or placebo for four weeks. Fatigue severity (BFI total score) was assessed at baseline and post-intervention. Data analysis was performed with SPSS 27 software, where statistical significance was considered at p < 0.05.Data were analyzed using ANCOVA, controlling for baseline scores. Effect size (Cohen’s d) and 95% confidence intervals (CI) were calculated.

Results

At baseline, mean fatigue scores were similar between groups (Intervention: 5.36 ± 1.18; Placebo: 5.35 ± 1.23). After four weeks, the intervention group demonstrated significant reductions in fatigue (3.99 ± 0.86 vs. 5.37 ± 1.27, p < 0.001), with an adjusted mean difference of − 1.38 (95% CI: − 1.90, − 0.86; Cohen’s d =  − 1.26). Significant improvements were also observed in general activity, walking ability, mood, and enjoyment of life in the intervention group. No treatment-related adverse events were reported.

Conclusion

Short-term Panax ginseng supplementation significantly reduced fatigue and improved multiple dimensions of daily functioning in GI cancer survivors, with excellent tolerability. These findings support Panax ginseng as a potential adjunctive intervention for CRF management within supportive care. Larger multicenter studies with extended follow-up are warranted.